ConductScience.org, home

Paper36910902

Irreversible electroporation for prostate cancer using PSMA PET-CT.

Shin D and 14 others. Prostate Int, 2023. Cited by 18 papers, by iCite.

Cite this record

ConductScience Library. Irreversible electroporation for prostate cancer using PSMA PET-CT. Papers, record 36910902. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36910902

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Irreversible electroporation for prostate cancer using PSMA PET-CT.
PubMed
Journal
Prostate Int
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
18
iCite
Relative citation ratio, by iCite
2.36
iCite
Revised in PubMed
2023-03-14
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shin DDongho
2Yoon CEChang Eil
3Kwon HJHyeok Jae
4Moon HWHyong Woo
5Park YHYong Hyun
6Cho HJHyuk Jin
7Ha USU-Syn
8Hong SHSung-Hoo
9Park SYSonya Youngju
10Ha SSeunggyun
11Hyun O JJoo
12Yoo IRIe Ryung
13Park CChansoo
14Chi DYDae Yoon
15Lee JYJi Youl

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129594551Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy.World J Urol2018https://conductscience.org/library/papers/29594551PubMed
234692586
Effectiveness of magnetic resonance imaging-targeted biopsy for detection of prostate cancer in comparison with systematic biopsy in our countries with low prevalence of prostate cancer: our first experience after 3 years.
Prostate Int2021https://conductscience.org/library/papers/34692586PubMed
321679984Characterizing clinically significant prostate cancer using template prostate mapping biopsy.J Urol2011https://conductscience.org/library/papers/21679984PubMed
427113966Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer.J Urol2016https://conductscience.org/library/papers/27113966PubMed
521111458Renal tissue ablation with irreversible electroporation: preliminary results in a porcine model.Urology2011https://conductscience.org/library/papers/21111458PubMed
62918819768Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends.Prostate Int2017https://conductscience.org/library/papers/29188197PubMed
717668937A study of the immunological response to tumor ablation with irreversible electroporation.Technol Cancer Res Treat2007https://conductscience.org/library/papers/17668937PubMed
835510079Diagnostic value of integrated 18F-PSMA-1007 PET/MRI compared with that of biparametric MRI for the detection of prostate cancer.Prostate Int2022https://conductscience.org/library/papers/35510079PubMed
931103721Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.Eur Urol Oncol2020https://conductscience.org/library/papers/31103721PubMed
1035059352A systematic review of outcomes after thermal and nonthermal partial prostate ablation.Prostate Int2021https://conductscience.org/library/papers/35059352PubMed
1121103304Irreversible electroporation: a novel image-guided cancer therapy.Gut Liver2010https://conductscience.org/library/papers/21103304PubMed
1227595377New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.Eur Urol2017https://conductscience.org/library/papers/27595377PubMed
1332458006A microdose clinical trial to evaluate [18F]Florastamin as a positron emission tomography imaging agent in patients with prostate cancer.Eur J Nucl Med Mol Imaging2021https://conductscience.org/library/papers/32458006PubMed
1434071934Irreversible Electroporation for Prostate Cancer.Life (Basel)2021https://conductscience.org/library/papers/34071934PubMed
1527574821Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer.Eur Urol2017https://conductscience.org/library/papers/27574821PubMed
1635510077Initial experience of single-port robot-assisted radical prostatectomy: A single surgeon's experience with technique description.Prostate Int2022https://conductscience.org/library/papers/35510077PubMed
1731161973Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes.Radiology2019https://conductscience.org/library/papers/31161973PubMed
1821360714Irreversible electroporation of the pancreas: definitive local therapy without systemic effects.J Surg Oncol2011https://conductscience.org/library/papers/21360714PubMed
1922808955Radical prostatectomy versus observation for localized prostate cancer.N Engl J Med2012https://conductscience.org/library/papers/22808955PubMed
2035059353Impact of preoperative factors on recovery of continence after artificial urinary sphincter implantation in postprostatectomy incontinence.Prostate Int2021https://conductscience.org/library/papers/35059353PubMed

See all 31 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.

PMIDTitleJournalYearIn PapersSource
42582915Results from the PRESERVE trial: an editorial commentary.Transl Androl Urol2026https://conductscience.org/library/papers/42582915PubMed
42568760The addition of PSMA PET in selecting candidates for prostate cancer focal therapy.BJUI Compass2026https://conductscience.org/library/papers/42568760PubMed
42382550Irreversible electroporation in focal therapy for prostate cancer: current status and future directions.Prostate Int2026https://conductscience.org/library/papers/42382550PubMed
41908232Irreversible electroporation for localized prostate cancer: risk-stratified oncologic outcomes and functional preservation.Prostate Int2026https://conductscience.org/library/papers/41908232PubMed
41522319Focal irreversible electroporation for the treatment of localised prostate cancer: a systematic review.Transl Androl Urol2025https://conductscience.org/library/papers/41522319PubMed
4147293218F-florastamin positron emission tomography/computed tomography in men with clinical suspicion of prostate cancer: A phase I prospective study.Prostate Int2025https://conductscience.org/library/papers/41472932PubMed
40940959Oncological Efficacy and Safety of Minimally Invasive Focal and Whole-Gland Interventions in the Treatment of Low- and Intermediate-Risk Prostate Cancer: A Systematic Review and Meta-Analysis.Cancers (Basel)2025https://conductscience.org/library/papers/40940959PubMed
40647385Oncological and Functional Outcomes of Hemi-Ablation Versus Focal Ablation for Localized Prostate Cancer Using Irreversible Electroporation.Cancers (Basel)2025https://conductscience.org/library/papers/40647385PubMed
40213348Clinical significance of primary tumor progression in metastatic hormone-sensitive prostate cancer.Prostate Int2025https://conductscience.org/library/papers/40213348PubMed
39939364Is there a role of PSMA-PET in focal therapy planning and follow-up?Prostate Cancer Prostatic Dis2026https://conductscience.org/library/papers/39939364PubMed
39028129Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review.World J Mens Health2025https://conductscience.org/library/papers/39028129PubMed
37627908Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer.Diagnostics (Basel)2023https://conductscience.org/library/papers/37627908PubMed
37444450Pulsed Electric Fields in Oncology: A Snapshot of Current Clinical Practices and Research Directions from the 4th World Congress of Electroporation.Cancers (Basel)2023https://conductscience.org/library/papers/37444450PubMed
37409098Diagnostic performance of MRI for prediction of recurrent prostate cancer after high-intensity focused ultrasound: a systematic review and meta-analysis.Prostate Int2023https://conductscience.org/library/papers/37409098PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
FOLH12346PubTator's text mininghttps://conductscience.org/library/genes/2346NCBI Gene
KLK3354PubTator's text mininghttps://conductscience.org/library/genes/354NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36910902

GET https://conductscience.org/api/papers/v1/36910902/references?page=2